Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
6 ClinicalTrials.gov REDEFINE 1 (NCT05567796)Registry record for the pivotal phase 3 CagriSema weight-management trial in adults without type 2 diabetes
Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1-induced metabolic reprograming
Brain 138 , 653663 (2015)
Market expansion has been supported by robust clinical outcomes, broader indications, and increasing adoption across global healthcare systems
US$ 25.87
US$ 26.38
US$ 29.78
US$ 22.88
US$ 26.68
US$ 27.79
US$ 23.81
US$ 26.23
US$ 29.60
US$ 20.44
US$ 23.02
US$ 28.71
